Chemical Component Summary

Identifiers (2S)-2-(2-fluorobiphenyl-4-yl)propanoic acid
(2S)-2-(3-fluoro-4-phenyl-phenyl)propanoic acid
Formula C15 H13 F O2
Molecular Weight 244.26 g/mol
Type non-polymer
Isomeric SMILES C[C@H](C(O)=O)c1ccc(c(F)c1)-c1ccccc1
InChI InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m0/s1

Chemical Details

Formal Charge 0
Atom Count 31
Chiral Atom Count 1
Chiral Atoms C12
Bond Count 32
Aromatic Bond Count 13

Drug Info: DrugBank

DrugBank ID DB00712   (Different stereochemistry)
Name Flurbiprofen
  • approved
  • investigational
Description Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
  • (+-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid
  • 2-(2-Fluorobiphenyl-4-yl)propanoic acid
  • 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid
  • 3-Fluoro-4-phenylhydratropic acid
  • Ansaid
Salts Flurbiprofen Sodium
Brand Names
  • Ansaid Tablets 100 mg
  • Ansaid Tablets 50 mg
  • Antiphlamine Pain Relieving
  • Apo-flurbiprofen Fc Tablets 100mg
  • Apo-flurbiprofen Fc Tablets 50mg
Affected Organism Humans and other mammals
Indication Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
Pharmacology Flurbiprofen, a nonsteroidal anti-inflammatory agent (NSAIA) of the propionic acid class, is structually and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen, and has similar pharmacological actions to other prototypica NSAIAs. Flurbiprofen exhibits antiinflammatory, analgesic, and antipyretic activities. The commercially available flurbiprofen is a racemic mixture of (+)S- and (-) R-enantiomers. The S-enantiomer appears to possess most of the anti-inflammatory, while both enantiomers may possess analgesic activity.
Mechanism of action Similar to other NSAIAs, the anti-inflammatory effect of flurbiprofen occurs via reversible inhibition of cyclooxygenase (COX), the enzyme responsible for the conversion of arachidonic acid to prostaglandin G2 (PGG2) and PGG2 to prostaglandin H2 (PGH2) in the prostaglandin synthesis pathway. This effectively decreases the concentration of prostaglandins involved in inflammation, pain, swelling and fever. Flurbiprofen is a non-selective COX inhibitor and inhibits the activity of both COX-1 and -2. It is also one of the most potent NSAIAs in terms of prostaglandin inhibitory activity.
Route of administration
  • Ophthalmic
  • Oral
  • Topical
  • Acids, Acyclic
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • M02AA19
  • R02AX01
  • M01AE09
  • S01BC04
  • 28:08.04.92
  • 52:08.20
CAS number 5104-49-4
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682